Background
Methods
Study population and propensity score matching
Statistical analysis
Results
Baseline characteristics
Variable | N (%) | Survival | Number of patients (%) | P value | |||||
---|---|---|---|---|---|---|---|---|---|
Median (IQR), mo | Adjuvant RT (N = 377) | Neoadjuvant RT (N = 377) | Surgery + Chemotherapy Only (N = 524) | ||||||
Age, years | 61.03 ± 9.52 | – | 61.88 ± 9.86 | 60.23 ± 9.80 | 61.72 ± 9.04 | 0.0645 | |||
Sex | 0.9669 | ||||||||
Male | 719 (56.26) | 58 (18, NR) | 210 | (55.70) | 213 | (56.50) | 296 | (56.49) | |
Female | 559 (43.74) | 65 (23, NR) | 167 | (44.30) | 164 | (43.50) | 228 | (43.51) | |
Race | 0.5785 | ||||||||
White | 1025 (80.20) | 61 (19, NR) | 303 | (80.37) | 309 | (81.96) | 413 | (78.82) | |
Black | 152 (11.89) | 79 (18, NR) | 47 | (12.47) | 43 | (11.41) | 62 | (11.83) | |
Other | 101 (7.90) | 57 (26, NR) | 27 | (7.16) | 25 | (6.63) | 49 | (9.35) | |
Histology | 0.8385 | ||||||||
Adenocarcinoma | 514 (40.22) | 54 (21, NR) | 144 | (38.20) | 150 | (39.79) | 220 | (41.98) | |
Squamous cell | 356 (27.86) | 69 (19, NR) | 109 | (28.91) | 104 | (27.59) | 143 | (27.29) | |
Others | 408 (31.92) | 79 (19, NR) | 124 | (32.89) | 123 | (32.63) | 161 | (30.73) | |
Grade | 0.0366 | ||||||||
I/ II | 389 (30.44) | 66 (26, NR) | 101 | (26.79) | 107 | (28.38) | 181 | (34.54) | |
III/ IV | 738 (57.75) | 48 (17, NR) | 226 | (59.95) | 218 | (57.82) | 294 | (56.11) | |
Unknown | 151 (11.82) | 103 (35, NR) | 50 | (13.26) | 52 | (13.79) | 49 | (9.35) | |
T classification | 0.4202 | ||||||||
T1 | 211 (16.51) | 73 (28, NR) | 70 | (18.57) | 55 | (14.59) | 86 | (16.41) | |
T2 | 535 (41.86) | 54 (20, NR) | 160 | (42.44) | 148 | (39.26) | 227 | (43.32) | |
T3 | 155 (12.13) | 46 (15, NR) | 40 | (10.61) | 54 | (14.32) | 61 | (11.64) | |
T4 | 377 (29.50) | 66 (18, NR) | 107 | (28.38) | 120 | (31.83) | 150 | (28.63) | |
N classification | 0.2972 | ||||||||
N0/N1 | 294 (23.00) | 81 (21, NR) | 82 | (21.75) | 80 | (21.22) | 132 | (25.19) | |
N2/N3 | 984 (77.00) | 56 (19, NR) | 295 | (78.25) | 297 | (78.78) | 392 | (74.81) | |
Extent of Resection | 0.9712 | ||||||||
Lobectomy or Bilobectomy | 1056 (82.63) | 64 (21, NR) | 311 | (82.49) | 313 | (83.02) | 432 | (82.44) | |
Pneumectomy | 222 (17.37) | 53 (15, NR) | 66 | (17.51) | 64 | (16.98) | 92 | (17.56) | |
Treatment regimen | – | ||||||||
Neoadjuvant RT | 377 (29.50) | 67 (20, NR) | – | – | – | – | – | – | |
Adjuvant RT | 377 (29.50) | 61 (17, NR) | – | – | – | – | – | – | |
Surgery + Chemotherapy Only | 524 (41.00) | 61 (22, NR) |
Survival
Variable | Cancer-Specific mortality | All-cause mortality | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age | 1.01 (1.00, 1.02) | 0.0027 | 1.02 (1.01, 1.02) | <.0001 |
Sex | ||||
Male |
Ref.
|
Ref.
| ||
Female | 0.86 (0.73, 1.02) | 0.0781 | 0.82 (0.70, 0.96) | 0.0108 |
Race | ||||
White |
Ref.
|
Ref.
| ||
Black | 0.88 (0.68, 1.14) | 0.3278 | 0.88 (0.69, 1.11) | 0.2748 |
Others | 0.96 (0.72, 1.27) | 0.7764 | 0.95 (0.73, 1.24) | 0.7033 |
Grade | ||||
I/ II |
Ref.
|
Ref.
| ||
III/ IV | 1.28 (1.07, 1.52) | 0.0066 | 1.26 (1.07, 1.49) | 0.0052 |
Unknown | 0.83 (0.61, 1.11) | 0.2023 | 0.82 (0.62, 1.08) | 0.1509 |
Histology | ||||
Adenocarcinoma |
Ref.
|
Ref.
| ||
Squamous cell | 0.82 (0.67, 1.00) | 0.0503 | 0.85 (0.70, 1.03) | 0.0928 |
Others | 0.88 (0.73, 1.06) | 0.1743 | 0.93 (0.78, 1.11) | 0.4148 |
T classification | ||||
T1 |
Ref.
|
Ref.
| ||
T2 | 1.27 (1.00, 1.60) | 0.0476 | 1.26 (1.01, 1.56) | 0.0375 |
T3 | 1.64 (1.20, 2.24) | 0.0020 | 1.49 (1.11, 2.00) | 0.0082 |
T4 | 1.34 (1.01, 1.78) | 0.0444 | 1.24 (0.95, 1.63) | 0.1121 |
N classification | ||||
N0/N1 |
Ref.
|
Ref.
| ||
N2/N3 | 1.50 (1.17, 1.92) | 0.0014 | 1.38 (1.09, 1.74) | 0.0065 |
Extent of Surgery | ||||
Lobectomy or Bilobectomy |
Ref.
|
Ref.
| ||
Pneumectomy | 1.16 (0.94, 1.43) | 0.1593 | 1.15 (0.95, 1.40) | 0.1585 |
Treatment regimen | ||||
Neoadjuvant RT |
Ref.
|
Ref.
| ||
Adjuvant RT | 1.10 (0.90, 1.35) | 0.3689 | 1.16 (0.96, 1.40) | 0.1273 |
Surgery + Chemotherapy-Only | 1.12 (0.93, 1.35) | 0.2382 | 1.18 (0.99, 1.41) | 0.0653 |
Variable | T1/2 & N2/3 | T3/4 & N0/1 | T3/4 & N2/3 |
---|---|---|---|
(N = 746) | (N = 294) | (N = 238) | |
Age | 1.01 (1.00, 1.02) | 1.00 (0.98, 1.02) | 1.03 (1.01, 1.05) ** |
Sex | |||
Male |
Ref.
|
Ref.
|
Ref.
|
Female | 0.81 (0.66, 1.01) | 0.92 (0.63, 1.34) | 0.97 (0.67, 1.40) |
Race | |||
White |
Ref.
|
Ref.
|
Ref.
|
Black | 0.87 (0.62, 1.21) | 0.80 (0.44, 1.45) | 0.97 (0.57, 1.65) |
Others | 0.97 (0.68, 1.38) | 1.13 (0.54, 2.34) | 0.88 (0.48, 1.62) |
Grade | |||
I/ II |
Ref.
|
Ref.
|
Ref.
|
III/ IV | 1.34 (1.07, 1.67) * | 1.67 (1.08, 2.58) * | 0.93 (0.63, 1.37) |
Unknown | 0.74 (0.51, 1.07) | 0.66 (0.30, 1.44) | 1.79 (0.93, 3.46) |
Histology | |||
Adenocarcinoma |
Ref.
|
Ref.
|
Ref.
|
Squamous cell | 1.01 (0.77, 1.31) | 0.69 (0.44, 1.07) | 0.66 (0.42, 1.05) |
Others | 0.98 (0.77, 1.25) | 0.94 (0.61, 1.44) | 0.72 (0.47, 1.11) |
Extent of Surgery | |||
Lobectomy or Bilobectomy |
Ref.
|
Ref.
|
Ref.
|
Pneumectomy | 1.04 (0.76, 1.43) | 1.00 (0.63, 1.59) | 1.80 (1.25, 2.61) ** |
Treatment regimen | |||
Neoadjuvant RT |
Ref.
|
Ref.
|
Ref.
|
Adjuvant RT | 1.11 (0.84, 1.47) | 1.54 (0.99, 2.38) | 0.74 (0.47, 1.16) |
Chemotherapy-Only | 1.42 (1.10, 1.83) ** | 0.65 (0.42, 1.02) | 0.93 (0.62, 1.41) |